Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2024Emerging Microbes & InfectionsOpen Access

Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium

View Full Paper
Ask AI
Bookmark
Share

Authors

LMLaura Marcos-VillarBPBeatriz PerdigueroMLMaría López‐Bravo

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Marcos-Villar et al. (2024) studied this question.

synapsesocial.com/papers/68e5dc63b6db64358757263dhttps://doi.org/10.1080/22221751.2024.2387906
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Homologous MVA and heterologous DREP/MVA vaccine regimens induce robust and durable immune responses against SARS-CoV-22026 · 1 citations
  2. 2Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA Consortium2024 · 14 citations
  3. 3Immunogenicity and efficacy of homologous and heterologous NDV and MVA SARS-CoV-2 vaccines in mice and hamsters2025
  4. 4Heterologous saRNA prime – multivalent protein boost strategy induces broad and durable immunity against SARS-CoV-2 and MERS-CoV2026 · 1 citations
  5. 5RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants2022 · 37 citations